The efficacy and safety of montelukast sodium in the prevention of bronchopulmonary dysplasia

Sang Bum Kim, Jang Hoon Lee, Juyoung Lee, Seung Han Shin, Ho Sun Eun, Soon Min Lee, Jin A. Sohn, Han Suk Kim, Byung Min Choi, Min Soo Park, Kook In Park, Ran Namgung, Moon Sung Park

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Purpose: The purpose of this study was to evaluate the efficacy and safety of Montelukast sodium in the prevention of bronchopulmonarydysplasia (BPD). Methods: The Interventional study was designed as a multicenter, prospective, and randomized trial, with open labeled and parallel-experimental groups, 66 infants were enrolled and allocated to either the case group (n=30) or the control group (n=36) based on gestational age (GA). Infants in the case group were given Montelukast sodium (Singulair) based on their body weight (BW). Zero week was defined as the start time of the study. Results: The incidence of moderate to severe BPD was not different between the groups (case group: 13 of 30[43.3%] vs. control group: 19 of 36 [52.8%], P=0.912). Additionally, secondary outcomes such as ventilation index, mean airway pressure and resort to systemic steroids were not significantly different. There were no serious adverse drug reactions in either group, and furthermore the rate of occurrence of mild drug related-events were not significantly different (case group: 10 of 42 [23.8%] vs. control group: 6 of 48 (15.8%), P=0.414). Conclusion: Montelukast was not effective in reducing moderate or severe BPD. There were no significant adverse drug events associated with Montelukast treatment.

Original languageEnglish
Pages (from-to)347-353
Number of pages7
JournalKorean Journal of Pediatrics
Volume58
Issue number9
DOIs
Publication statusPublished - 2015 Jan 1

Fingerprint

montelukast
Bronchopulmonary Dysplasia
Safety
Drug-Related Side Effects and Adverse Reactions
Control Groups
Time and Motion Studies
Gestational Age
Ventilation
Steroids
Body Weight
Pressure

Keywords

  • Broncopulmonary dysplasia
  • Leukotriene antagonists
  • Montelukast
  • Pharmacokinetics
  • Premature infant

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Pediatrics

Cite this

Kim, S. B., Lee, J. H., Lee, J., Shin, S. H., Eun, H. S., Lee, S. M., ... Park, M. S. (2015). The efficacy and safety of montelukast sodium in the prevention of bronchopulmonary dysplasia. Korean Journal of Pediatrics, 58(9), 347-353. https://doi.org/10.3345/kjp.2015.58.9.347

The efficacy and safety of montelukast sodium in the prevention of bronchopulmonary dysplasia. / Kim, Sang Bum; Lee, Jang Hoon; Lee, Juyoung; Shin, Seung Han; Eun, Ho Sun; Lee, Soon Min; Sohn, Jin A.; Kim, Han Suk; Choi, Byung Min; Park, Min Soo; Park, Kook In; Namgung, Ran; Park, Moon Sung.

In: Korean Journal of Pediatrics, Vol. 58, No. 9, 01.01.2015, p. 347-353.

Research output: Contribution to journalArticle

Kim, SB, Lee, JH, Lee, J, Shin, SH, Eun, HS, Lee, SM, Sohn, JA, Kim, HS, Choi, BM, Park, MS, Park, KI, Namgung, R & Park, MS 2015, 'The efficacy and safety of montelukast sodium in the prevention of bronchopulmonary dysplasia', Korean Journal of Pediatrics, vol. 58, no. 9, pp. 347-353. https://doi.org/10.3345/kjp.2015.58.9.347
Kim, Sang Bum ; Lee, Jang Hoon ; Lee, Juyoung ; Shin, Seung Han ; Eun, Ho Sun ; Lee, Soon Min ; Sohn, Jin A. ; Kim, Han Suk ; Choi, Byung Min ; Park, Min Soo ; Park, Kook In ; Namgung, Ran ; Park, Moon Sung. / The efficacy and safety of montelukast sodium in the prevention of bronchopulmonary dysplasia. In: Korean Journal of Pediatrics. 2015 ; Vol. 58, No. 9. pp. 347-353.
@article{a9cd8f5ebc24405cba05c774ec558621,
title = "The efficacy and safety of montelukast sodium in the prevention of bronchopulmonary dysplasia",
abstract = "Purpose: The purpose of this study was to evaluate the efficacy and safety of Montelukast sodium in the prevention of bronchopulmonarydysplasia (BPD). Methods: The Interventional study was designed as a multicenter, prospective, and randomized trial, with open labeled and parallel-experimental groups, 66 infants were enrolled and allocated to either the case group (n=30) or the control group (n=36) based on gestational age (GA). Infants in the case group were given Montelukast sodium (Singulair) based on their body weight (BW). Zero week was defined as the start time of the study. Results: The incidence of moderate to severe BPD was not different between the groups (case group: 13 of 30[43.3{\%}] vs. control group: 19 of 36 [52.8{\%}], P=0.912). Additionally, secondary outcomes such as ventilation index, mean airway pressure and resort to systemic steroids were not significantly different. There were no serious adverse drug reactions in either group, and furthermore the rate of occurrence of mild drug related-events were not significantly different (case group: 10 of 42 [23.8{\%}] vs. control group: 6 of 48 (15.8{\%}), P=0.414). Conclusion: Montelukast was not effective in reducing moderate or severe BPD. There were no significant adverse drug events associated with Montelukast treatment.",
keywords = "Broncopulmonary dysplasia, Leukotriene antagonists, Montelukast, Pharmacokinetics, Premature infant",
author = "Kim, {Sang Bum} and Lee, {Jang Hoon} and Juyoung Lee and Shin, {Seung Han} and Eun, {Ho Sun} and Lee, {Soon Min} and Sohn, {Jin A.} and Kim, {Han Suk} and Choi, {Byung Min} and Park, {Min Soo} and Park, {Kook In} and Ran Namgung and Park, {Moon Sung}",
year = "2015",
month = "1",
day = "1",
doi = "10.3345/kjp.2015.58.9.347",
language = "English",
volume = "58",
pages = "347--353",
journal = "Korean Journal of Pediatrics",
issn = "1783-1061",
publisher = "Korean Pediatric Society",
number = "9",

}

TY - JOUR

T1 - The efficacy and safety of montelukast sodium in the prevention of bronchopulmonary dysplasia

AU - Kim, Sang Bum

AU - Lee, Jang Hoon

AU - Lee, Juyoung

AU - Shin, Seung Han

AU - Eun, Ho Sun

AU - Lee, Soon Min

AU - Sohn, Jin A.

AU - Kim, Han Suk

AU - Choi, Byung Min

AU - Park, Min Soo

AU - Park, Kook In

AU - Namgung, Ran

AU - Park, Moon Sung

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Purpose: The purpose of this study was to evaluate the efficacy and safety of Montelukast sodium in the prevention of bronchopulmonarydysplasia (BPD). Methods: The Interventional study was designed as a multicenter, prospective, and randomized trial, with open labeled and parallel-experimental groups, 66 infants were enrolled and allocated to either the case group (n=30) or the control group (n=36) based on gestational age (GA). Infants in the case group were given Montelukast sodium (Singulair) based on their body weight (BW). Zero week was defined as the start time of the study. Results: The incidence of moderate to severe BPD was not different between the groups (case group: 13 of 30[43.3%] vs. control group: 19 of 36 [52.8%], P=0.912). Additionally, secondary outcomes such as ventilation index, mean airway pressure and resort to systemic steroids were not significantly different. There were no serious adverse drug reactions in either group, and furthermore the rate of occurrence of mild drug related-events were not significantly different (case group: 10 of 42 [23.8%] vs. control group: 6 of 48 (15.8%), P=0.414). Conclusion: Montelukast was not effective in reducing moderate or severe BPD. There were no significant adverse drug events associated with Montelukast treatment.

AB - Purpose: The purpose of this study was to evaluate the efficacy and safety of Montelukast sodium in the prevention of bronchopulmonarydysplasia (BPD). Methods: The Interventional study was designed as a multicenter, prospective, and randomized trial, with open labeled and parallel-experimental groups, 66 infants were enrolled and allocated to either the case group (n=30) or the control group (n=36) based on gestational age (GA). Infants in the case group were given Montelukast sodium (Singulair) based on their body weight (BW). Zero week was defined as the start time of the study. Results: The incidence of moderate to severe BPD was not different between the groups (case group: 13 of 30[43.3%] vs. control group: 19 of 36 [52.8%], P=0.912). Additionally, secondary outcomes such as ventilation index, mean airway pressure and resort to systemic steroids were not significantly different. There were no serious adverse drug reactions in either group, and furthermore the rate of occurrence of mild drug related-events were not significantly different (case group: 10 of 42 [23.8%] vs. control group: 6 of 48 (15.8%), P=0.414). Conclusion: Montelukast was not effective in reducing moderate or severe BPD. There were no significant adverse drug events associated with Montelukast treatment.

KW - Broncopulmonary dysplasia

KW - Leukotriene antagonists

KW - Montelukast

KW - Pharmacokinetics

KW - Premature infant

UR - http://www.scopus.com/inward/record.url?scp=84941561331&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84941561331&partnerID=8YFLogxK

U2 - 10.3345/kjp.2015.58.9.347

DO - 10.3345/kjp.2015.58.9.347

M3 - Article

AN - SCOPUS:84941561331

VL - 58

SP - 347

EP - 353

JO - Korean Journal of Pediatrics

JF - Korean Journal of Pediatrics

SN - 1783-1061

IS - 9

ER -